Casi Pharmaceuticals announces that the China National Medical Products Administration has approved the company’s Clinical Trial Application for CB-5339, a first-in-class VCP/p97 inhibitor from Cleave Therapeutics. CASI is planning a Phase 1 development program in China of CB-5339 as a single agent to evaluate the PK/safety profile, select the Recommended Phase 2 Dose, and assess early signs of clinical efficacy. The Phase 1 development program is expected to start in 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CASI:
